NCT00952276View on ClinicalTrials.gov

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

PHASE2CompletedINTERVENTIONAL
Enrollment

548

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions
InfluenzaSwine-origin A/H1N1 Influenza
Interventions
BIOLOGICAL

Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant

0.5 mL, Intramuscular on Day 0

BIOLOGICAL

Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant

0.5 mL, Intramuscular on Day 0

BIOLOGICAL

Monovalent Subvirion A/H1N1 influenza vaccine

0.5 mL, Intramuscular on Day 0

BIOLOGICAL

Monovalent Subvirion A/H1N1 influenza vaccine

0.5 mL, Intramuscular on Day 0

BIOLOGICAL

Normal saline solution

0.5 mL, Intramuscular on Day 0

Trial Locations (15)

14609

Rochester

15025

Jefferson Hills

16127

Grove City

27612

Raleigh

33143

South Miami

38305

Jackson

44122

Cleveland

45227

Cincinnati

65802

Springfield

84109

Salt Lake City

84124

Salt Lake City

84663

Springville

92708

Fountain Valley

92801

Anaheim

02886

Warwick

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY